Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer

Nature Communications

Volumn 6, Issue , 2015, Pages

  Sun, Yi ^a   Sheng, Zhen ^a   Ma, Chao ^a   Tang, Kailin ^a   Zhu, Ruixin ^a   Wu, Zhuanbin ^b   Shen, Ruling ^a,b   Feng, Jun ^a   Wu, Dingfeng ^a   Huang, Danyi ^a   Huang, Dandan ^a   Fei, Jian ^a   Liu, Qi ^a   Cao, Zhiwei ^a  

^a TONGJI UNIVERSITY   (China)

^b Shanghai Research Center for Model Organisms   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; AFATINIB; ANTINEOPLASTIC AGENT; DASATINIB; ERLOTINIB; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; MEPACRINE; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; TOREMIFENE;

ALGORITHM; CANCER; CELLS AND CELL COMPONENTS; CYPRINID; DISEASE TREATMENT; DRUG; EXPERIMENTAL STUDY; GENOMICS; LITERATURE REVIEW; PREDICTION; TOXICITY;

A549 CELL LINE; ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EMBRYO; GENOMICS; HUMAN; IN VIVO STUDY; LC50; LUNG CANCER; MCF 7 CELL LINE; NONHUMAN; PREDICTION; TRANSCRIPTOMICS; TUMOR XENOGRAFT; ANIMAL; DRUG SCREENING; MCF-7 CELL LINE; NEOPLASMS; THEORETICAL MODEL; VALIDATION STUDY; ZEBRA FISH;

DANIO RERIO;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG SYNERGISM; GENOMICS; HUMANS; MCF-7 CELLS; MODELS, THEORETICAL; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 84942904699     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9481     Document Type: Article

References (42)

1. Al-Lazikani, B., Banerji, U. & Workman, P. Combinatorial drug therapy for cancer in the post-genomic era. Nat. Biotechnol. 30, 679-692 (2012).
2. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
3. Held, M. A. et al. Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Cancer Discov. 3, 52-67 (2013).
4. Mathews Griner, L. A. et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl Acad. Sci. USA 111, 2349-2354 (2014).
5. Cokol, M. et al. Systematic exploration of synergistic drug pairs. Mol. Syst. Biol. 7, 544 (2011).
6. Sun, X., Vilar, S. & Tatonetti, N. P. High-throughput methods for combinatorial drug discovery. Sci. Transl. Med. 5, 205rv201 (2013).
7. Zhao, J., Zhang, X. S. & Zhang, S. Predicting cooperative drug effects through the quantitative cellular profiling of response to individual drugs. CPT Pharmacometrics Syst. Pharmacol. 3, e102 (2014).
8. Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213-1222 (2014).
9. Huang, L. et al. DrugComboRanker: drug combination discovery based on target network analysis. Bioinformatics. 30, i228-i236 (2014).
10. Liu, Y. et al. DCDB 2.0: a major update of the drug combination database. Database (Oxford) 2014, bau124 (2014).
11. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009).
12. Zhao, X. M. et al. Prediction of drug combinations by integrating molecular and pharmacological data. PLoS Comput. Biol. 7, e1002323 (2011).
13. Bansal, M. et al. A community computational challenge to predict the activity of pairs of compounds. Nat. Biotechnol. 32, 1213-1222 (2014).
14. Zhou, D., Weston, J., Gretton, A., Bousquet, O. & aB, S. Ranking on data manifolds. Adv. Neural. Inf. Process Syst. 16, 169-176 (2004).
15. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467-480 (2011).
16. Dinu, Liviu P. & Manea, F. An efficient approach for the rank aggregation problem. Theor. Comp. Sci. 359, 455-461 (2006).
17. Iwuchukwu, O. F., Tallarida, R. J. & Nagar, S. Resveratrol in combination with other dietary polyphenols concomitantly enhances antiproliferation and UGT1A1 induction in Caco-2 cells. Life Sci. 88, 1047-1054 (2011).
18. Medina, P. J. & Goodin, S. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin. Ther. 30, 1426-1447 (2008).
19. Bruzzese, F. et al. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol. Cancer Ther. 8, 3075-3087 (2009).
20. Soule, S. E. et al. Combined anti-microtubule therapy: a phase II study of weekly docetaxel plus estramustine in patients with metastatic breast cancer. Ann. Oncol. 13, 1612-1615 (2002).
21. Adel, A. L., Dorr, R. T. & Liddil, J. D. The effect of anticancer drug sequence in experimental combination chemotherapy. Cancer Invest. 11, 15-24 (1993).
22. Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B. & Sorger, P. K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
23. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
24. Manevitz, Larry M. & Yousef, M. One-class SVMs for document classification. J. Mach. Learn. Res. 2, 139-154 (2001).
25. Lee, S. Y. et al. PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression. Lung. Cancer 51, 297-301 (2006).
26. Konantz, M. et al. Zebrafish xenografts as a tool for in vivo studies on human cancer. Ann. N. Y. Acad. Sci. 1266, 124-137 (2012).
27. Stoletov, K. & Klemke, R. Catch of the day: zebrafish as a human cancer model. Oncogene 27, 4509-4520 (2008).
28. Graham, R. M., Thompson, J. W. & Webster, K. A. Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis. Oncotarget 5, 1162-1173 (2014).
29. Lee, J. H., Shim, J. W., Choi, Y. J., Heo, K. & Yang, K. The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1alpha expression. Oncol. Rep. 29, 917-924 (2013).
30. Breuleux, M. et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol. Cancer Ther. 8, 742-753 (2009).
31. Chao, T. T. et al. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. Oncotarget 6, 2164-2179 (2015).
32. Coco, S. et al. Afatinib resistance in non-small cell lung cancer involves the PI3K/AKT and MAPK/ERK signalling pathways and epithelial-tomesenchymal transition. Targeted Oncol. 10, 393-404 (2014).
33. Zhang, S. et al. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation. Oncotarget 6, 5832-5845 (2015).
34. Vail, M. E. et al. Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res. 74, 4470-4481 (2014).
35. Knox, C. et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 39, D1035-D1041 (2011).
36. Zhu, F. et al. Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 40, D1128-D1136 (2012).
37. Huang, da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
38. Ortutay, C. & Vihinen, M. Identification of candidate disease genes by integrating Gene Ontologies and protein-interaction networks: case study of primary immunodeficiencies. Nucleic Acids Res. 37, 622-628 (2009).
39. Westerfield, M. The Zebrafish Book: A Guide For The Laboratory Use Of Zebrafish Danio (Brachydanio) rerio (1995).
40. Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dynamics 203, 253-310 (1995).
41. Lawson, N. D. & Weinstein, B. M. In vivo imaging of embryonic vascular development using transgenic zebrafish. Dev. Biol. 248, 307-318 (2002).
42. White, R. M. et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2, 183-189 (2008).